- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Nanovalent Pharmaceuticals of Bozeman, Montana has entered into a collaboration with oncology researchers at Children's Hospital of Los Angeles. The partnership will focus on generating efficacy data in murine models of Ewing's Sarcoma and Acute Lymphoblastic Leukemia utilizing Nanovalent's drug candidates NANO-EW and NANO-ALL.
NANO-EW, NanoValent's lead cancer drug candidate is a transferrin surface targeted nanoparticle loaded with the chemotherapeutic SN38. The Company's primary indication is Ewing's Sarcoma. However, the firm intends to expand development efforts to include non-small cell lung cancer and hepatocellular carcinoma.
NANO-ALL is a transferrin surface targeted nanoparticle delivering siRNA fragments intended to silence gene sequences specific to acute lymphoblastic leukemia.
The Company is developing therapeutics against pediatric and adult cancers using proprietary polymerized liposomal nanoparticle (PLN) drug delivery technology.
About Nanovalent Pharmaceuticals
NanoValent Pharmaceuticals, Inc. (NVP) is a Delaware C-corporation commercializing a drug delivery platform that differentiates itself from other particle delivery systems through several key features. NanoValent particles are highly robust, customizable, stable, cheap, and easy to manufacture. The technology is capable of delivering a wide array of drug molecules or drug cocktails using multiple tissue targeting ligands. While other firms have successfully used targeted particles to deliver pharmaceuticals, few competitors have a payload specific custom offering with the flexibility to target using any surface ligand and deliver virtually any drug or biological payload. The platform product and manufacturing protocols are complete and the company has secured patents along with significant grant funding. The Companyís strategy is to develop several internal delivery programs, while leveraging the versatility of the platform technology providing custom drug delivery solutions to academic and private drug development programs. Internal development efforts are focused on vaccines, cancer therapeutics, and RNAi delivery.
James Hamilton MD, MBA
Jon Nagy PhD
Tim Trich MD, PhD
Chief Medical Officer
Copyright © NanoValent Pharmaceuticals, Inc.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016
Yale researchersí technology turns wasted heat into power June 27th, 2016
FEI Launches Helios G4 DualBeam Series for Materials Science: The Helios G4 DualBeam Series features new capabilities to enable scientists and engineers to answer the most demanding and challenging scientific questions June 27th, 2016
FEI and University of Liverpool Announce QEMSCAN Research Initiative: University of Liverpool will utilize FEIís QEMSCAN technology to gain a better insight into oil and gas reserves & potentially change the approach to evaluating them June 22nd, 2016
French Research Team Helps Extend MRI Detection of Diseases & Lower Health-Care Costs: CEA, INSERM and G2ELab Brings Grenoble Regionís Expertise In Advanced Medicine & Magnetism Applications to H2020 IDentIFY Project June 21st, 2016